Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 555Lymphoma 447Precursor Cell Lymphoblastic Leukemia-Lymphoma 413Lymphoma, Large B-Cell, Diffuse 348Leukemia 346Multiple Myeloma 336Lymphoma, Non-Hodgkin 317Leukemia, Myeloid, Acute 289Leukemia, Lymphocytic, Chronic, B-Cell 286Lymphoma, Follicular 241Burkitt Lymphoma 217Myelodysplastic Syndromes 211Lymphoma, Mantle-Cell 202Hodgkin Disease 193Recurrence 155Lymphoma, B-Cell, Marginal Zone 142Melanoma 136Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Ovarian Neoplasms 96Triple Negative Breast Neoplasms 94Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

Oxaliplatin 11Mitomycin 11Leucovorin 7Hyperthermic Intraperitoneal Chemotherapy 7Irinotecan 6Fluorouracil 6Cisplatin 4Capecitabine 4Surveys and Questionnaires 3Doxorubicin 3Cytoreduction Surgical Procedures 3dehydroftorafur 2Trastuzumab 2Thalidomide 2Mitozytrex 2Melphalan 2Interleukin-12 Subunit p35 2Floxuridine 2Drug Therapy 2Cetuximab 2Biopsy 2tipifarnib 1surufatinib 1sodium thiosulfate 1sintilimab 1nintedanib 1nilotinib 1motexafin lutetium 1irinotecan sucrosofate 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Appendiceal Neoplasms × Cyclophosphamide × Clear all
NCT02963831 2022-12-22

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Ludwig Institute for Cancer Research

Phase 1/2 Completed
67 enrolled 16 charts
GastrointestinalGynecologic

Appendiceal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡